$XBI $126 -1%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$CYDY +8% CytoDyn Receives First Purchase Order from Chiral Pharma Corporation for Use of Leronlimab Under CSP for COVID-19 Patients in the Philippines. source
$ADMP +2% NDA for ZIMHI™ submitted to the FDA; Phase 2/3 clinical trial preparation initiated for Tempol for treatment of COVID-19. source
Pipeline Updates
$ACRX +3% Rapid Discharge with Minimal PACU Opioids was Key Message During Presentation of DSUVIA® For Analgesia in Plastic Surgery Procedures at the California Society of Plastic Surgeons Annual Meeting. source
$JAGX +13% Napo EU S.p.A., Jaguar Health’s Italian Subsidiary, Provides Updates on Plans to Pursue Conditional Marketing Authorization in the EU. source
$ANVS +25% Annovis Bio’s ANVS401 Improves Speed and Accuracy in Alzheimer’s and in Parkinson’s Patients. source
$TCON +2% TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial. source
$MCRB -4% Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD). source
$SELB +3% Selecta Biosciences Announces Frontiers in Immunology Publication Showcasing the Enhanced Hepatic Tolerogenic Potential of ImmTOR™ . source
$AKRO +1% Akero Therapeutics to Present Efruxifermin (EFX) Results Showing Histologic Improvement in EFX-Treated F4 Cirrhotic Patients as a Late-Breaker Oral Presentation at the 2021 International Liver Congress. source
$LEGN -2% Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings. source
$VIRX -5% Viracta Therapeutics Announces the Initiation of NAVAL-1, a Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma. source
$PRTK +21% Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP). source
$BBIO +4% BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1. source
$CTIC +6% CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis. source
$ALKS +2% Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder. source
$CRBP -5% Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases. source
$SPPI +7% Spectrum Pharmaceuticals Announces That the ROLONTIS® (eflapegrastim) Pre-Approval Inspection Has Been Initiated. source
$DTIL +3% Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo. source
$STRO -3% Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany. source
$LCTX +27% Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated With OpRegen® RPE Cells. source
$AKBA -3% Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis. source
Financial Updates
$SEEL +9% Seelos Therapeutics Announces its Inclusion in the First U.S. Listed Exchange Traded Fund (ETF) Focused on Psychedelics. source
Posted by FS